Supplements

Low-sodium oxybate reduces daytime sleepiness and improves nighttime sleep in participants with narcolepsy

In a phase 4 open-label study of 34 participants with narcolepsy (type 1 or 2), low-sodium oxybate (LXB) significantly reduced daytime sleepiness, with a least-squares mean change in Epworth Sleepiness Scale score of -7.7 (P < 0.0001). Nighttime sleep improvements included a 45-minute increase in deep sleep (N3 duration), a reduction in transitions to lighter sleep stages by 13.1, and 3.2 fewer nocturnal awakenings.

1 min read•Updated Jul 7, 2026•0 RCTs•View structured evidence →
Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism☆☆☆☆☆
Safety☆☆☆☆☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Low-sodium oxybate reduces daytime sleepiness and improves nighttime sleep in participants with narcolepsy The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).

The Claim

Low-sodium oxybate reduces daytime sleepiness and improves nighttime sleep in participants with narcolepsy

This conclusion is most relevant to: Participants with narcolepsy type 1 (n=16) or type 2 (n=18) who completed the study (34 total analyzed).

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study. (Neurology and therapy, 2026) —

How It Works

The proposed biological pathway:

  • ▸LXB contains calcium, magnesium, potassium, and sodium oxybates
  • ▸Oxybate acts on GABA-B receptors to promote slow-wave sleep
  • ▸Reduced transitions to lighter sleep stages and fewer nocturnal awakenings
  • ▸Result: Increased deep sleep duration and reduced daytime sleepiness

Who Might Benefit

Evidence fit by population:

  • ▸Participants with narcolepsy type 1 (n=16) or type 2 (n=18) who completed the study (34 total analyzed)

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Open-label design without a placebo control group limits causal inference
  • ▸Small sample size (n=34 completers) and short treatment duration (5-12 weeks) may not reflect long-term effects

References

  1. 1.Schneider LD, Ruoff CM, Plante DT, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Cairns A. “Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study..” Neurology and therapy, 2026. PMID: 42060037 DOI: 10.1007/s40120-026-00921-3
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.